What is known and objective With the high cost, the long‐term persistence of new oral
anticoagulants (NOACs) was lower than that of warfarin in Chinese patients with non …

Atrial fibrillation (AF) is associated with increased risk of stroke that can be attenuated with
vitamin K antagonists (VKAs). Vitamin K antagonist use is limited, in part, by the high …

Background Non-vitamin K oral antagonist anticoagulants (NOACs) have been widely used
in stroke prevention in atrial fibrillation (SPAF). The aim of this study was to compare the …

Atrial fibrillation (AF) is a common arrhythmia and the leading cause of stroke, an event with
high human and economic burden. Novel oral anticoagulants have been approved in many …

Background and objective The increasing availability of real-world evidence (RWE) about
safety and effectiveness of direct non-vitamin K oral anticoagulants (DOACs) for the …

Background Non-vitamin K antagonist oral anticoagulants (NOACs), including apixaban, are
recommended for prevention of stroke and systemic embolism in non-valvular atrial …

Aim: To compare the risk of stroke, systemic thromboembolism and bleeding, in patients
initiating apixaban or acenocoumarol for the treatment of nonvalvular atrial fibrillation …

Abstract Introduction The Apixaban for the Reduction in Stroke and Other Thromboembolic
Events in Atrial Fibrillation (ARISTOTLE), Randomized Evaluation of Long-term …

Objective: Dabigatran and rivaroxaban have been approved by the US FDA to reduce the
risk of stroke and systemic embolism in non-valvular atrial fibrillation (NVAF) patients. Newly …

Background The ARISTOTLE study investigated apixaban, at a dose of 5 mg PO bid, for the
prevention of stroke in patients with atrial fibrillation; however, it has been noted anecdotally …